Sulfamylon

Mafenide Acetate


Mylan Institutional Inc.
Human Prescription Drug
NDC 51079-624
Sulfamylon also known as Mafenide Acetate is a human prescription drug labeled by 'Mylan Institutional Inc.'. National Drug Code (NDC) number for Sulfamylon is 51079-624. This drug is available in dosage form of Powder, For Solution. The names of the active, medicinal ingredients in Sulfamylon drug includes Mafenide Acetate - 50 g/1 . The currest status of Sulfamylon drug is Active.

Drug Information:

Drug NDC: 51079-624
The labeler code and product code segments of the National Drug Code number, separated by a hyphen. Asterisks are no longer used or included within the product code segment to indicate certain configurations of the NDC.
Proprietary Name: Sulfamylon
Also known as the trade name. It is the name of the product chosen by the labeler.
Product Type: Human Prescription Drug
Indicates the type of product, such as Human Prescription Drug or Human OTC Drug. This data element corresponds to the “Document Type” of the SPL submission for the listing.
Non Proprietary Name: Mafenide Acetate
Also known as the generic name, this is usually the active ingredient(s) of the product.
Labeler Name: Mylan Institutional Inc.
Name of Company corresponding to the labeler code segment of the ProductNDC.
Dosage Form: Powder, For Solution
The translation of the DosageForm Code submitted by the firm. There is no standard, but values may include terms like `tablet` or `solution for injection`.The complete list of codes and translations can be found www.fda.gov/edrls under Structured Product Labeling Resources.
Status: Active
FDA does not review and approve unfinished products. Therefore, all products in this file are considered unapproved.
Substance Name:MAFENIDE ACETATE - 50 g/1
This is the active ingredient list. Each ingredient name is the preferred term of the UNII code submitted.
Route Details:TOPICAL
The translation of the Route Code submitted by the firm, indicating route of administration. The complete list of codes and translations can be found at www.fda.gov/edrls under Structured Product Labeling Resources.

Marketing Information:

An openfda section: An annotation with additional product identifiers, such as NUII and UPC, of the drug product, if available.
Marketing Category: NDA
Product types are broken down into several potential Marketing Categories, such as New Drug Application (NDA), Abbreviated New Drug Application (ANDA), BLA, OTC Monograph, or Unapproved Drug. One and only one Marketing Category may be chosen for a product, not all marketing categories are available to all product types. Currently, only final marketed product categories are included. The complete list of codes and translations can be found at www.fda.gov/edrls under Structured Product Labeling Resources.
Marketing Start Date: 05 Jun, 1998
This is the date that the labeler indicates was the start of its marketing of the drug product.
Marketing End Date: 30 Apr, 2023
This is the date the product will no longer be available on the market. If a product is no longer being manufactured, in most cases, the FDA recommends firms use the expiration date of the last lot produced as the EndMarketingDate, to reflect the potential for drug product to remain available after manufacturing has ceased. Products that are the subject of ongoing manufacturing will not ordinarily have any EndMarketingDate. Products with a value in the EndMarketingDate will be removed from the NDC Directory when the EndMarketingDate is reached.
Application Number: NDA019832
This corresponds to the NDA, ANDA, or BLA number reported by the labeler for products which have the corresponding Marketing Category designated. If the designated Marketing Category is OTC Monograph Final or OTC Monograph Not Final, then the Application number will be the CFR citation corresponding to the appropriate Monograph (e.g. “part 341”). For unapproved drugs, this field will be null.
Listing Expiration Date: 25 Dec, 2025
This is the date when the listing record will expire if not updated or certified by the firm.

OpenFDA Information:

An openfda section: An annotation with additional product identifiers, such as NUII and UPC, of the drug product, if available.
Manufacturer Name:Mylan Institutional Inc.
Name of manufacturer or company that makes this drug product, corresponding to the labeler code segment of the NDC.
RxCUI:251575
285024
The RxNorm Concept Unique Identifier. RxCUI is a unique number that describes a semantic concept about the drug product, including its ingredients, strength, and dose forms.
Original Packager:Yes
Whether or not the drug has been repackaged for distribution.
UNII:RQ6LP6Z0WY
Unique Ingredient Identifier, which is a non-proprietary, free, unique, unambiguous, non-semantic, alphanumeric identifier based on a substance’s molecular structure and/or descriptive information.
Pharmacologic Class:Methylated Sulfonamide Antibacterial [EPC]
Methylated Sulfonamides [EXT]
These are the reported pharmacological class categories corresponding to the SubstanceNames listed above.

Packaging Information:

Package NDCDescriptionMarketing Start DateMarketing End DateSample Available
51079-624-855 PACKET in 1 CARTON (51079-624-85) / 1 POWDER, FOR SOLUTION in 1 PACKET (51079-624-84)05 Jun, 199830 Apr, 2023No
Package NDC number, known as the NDC, identifies the labeler, product, and trade package size. The first segment, the labeler code, is assigned by the FDA. Description tells the size and type of packaging in sentence form. Multilevel packages will have the descriptions concatenated together.

Product Elements:

Sulfamylon mafenide acetate mafenide acetate mafenide

Indications and Usage:

Indications and usage sulfamylon ® for 5% topical solution is indicated for use as an adjunctive topical antimicrobial agent to control bacterial infection when used under moist dressings over meshed autografts on excised burn wounds.

Warnings:

Warnings fatal hemolytic anemia with disseminated intravascular coagulation, presumably related to a glucose-6-phosphate dehydrogenase deficiency, has been reported following therapy with mafenide acetate.

General Precautions:

General mafenide acetate and its metabolite, p -carboxybenzenesulfonamide, inhibit carbonic anhydrase, which may result in metabolic acidosis, usually compensated by hyperventilation. in the presence of impaired renal function, high blood levels of mafenide acetate and its metabolite may exaggerate the carbonic anhydrase inhibition. therefore, close monitoring of acid-base balance is necessary, particularly in patients with extensive second-degree or partial-thickness burns and in those with pulmonary or renal dysfunction. some burn patients treated with mafenide acetate have also been reported to manifest an unexplained syndrome of masked hyperventilation with resulting respiratory alkalosis (slightly alkaline blood ph, low arterial pco 2 , and decreased total co 2 ); change in arterial po 2 is variable. the etiology and significance of these findings are unknown. mafenide acetate should be used with caution in burn patients with acute renal failure. fungal colonization may occur conc
omitantly with reduction of bacterial growth in the burn wound. however, systemic fungal infection through the infected burn wound is rare.

Dosage and Administration:

Dosage and administration sulfamylon ® for 5% topical solution directions for preparation of the solution sulfamylon ® (mafenide acetate) for 5% topical solution is supplied as a sterile powder and is to be reconstituted with sterile water for irrigation, usp or 0.9% sodium chloride irrigation, usp. aseptic techniques should be observed during preparation of the solution. premeasured quantities of 50 g of mafenide acetate powder are provided in sterile packets. the entire quantity of sulfamylon ® should be emptied into a suitable container which contains 1000 ml of sterile water for irrigation, usp or 0.9% sodium chloride irrigation, usp and mixed until completely dissolved. the reconstituted solution may be held up to 28 days after preparation if stored in unopened containers. once a container is opened, any unused portion should be discarded after 48 hours. store the reconstituted solution at 20° to 25°c (68° to 77°f). limited storage periods at 15° to 30°c
(59° to 86°f) are acceptable. not for injection - for topical use only. directions for use of the solution the grafted area should be covered with one layer of fine mesh gauze. an eight-ply burn dressing should be cut to the size of the graft and wetted with sulfamylon ® for 5% topical solution using an irrigation syringe and/or irrigation tubing until leaking is noticeable. if irrigation tubing is used, the tubing should be placed over the burn dressing in contact with the wound and covered with a second piece of eight-ply dressing. the irrigation dressing should be secured with a bolster dressing and wrapped as appropriate. the gauze dressing should be kept wet. in clinical studies, this has been accomplished by irrigating with a syringe or injecting the solution into the irrigation tubing every 4 hours or as necessary. if irrigation tubing is not used, the gauze dressing may be moistened every 6-8 hours or as necessary to keep wet. wound dressings may be left undisturbed, except for the irrigations, for up to five days. additional soaks may be initiated until graft take is complete. maceration of skin may result from wet dressings applied for intervals as short as 24 hours. treatment is usually continued until autograft vascularization occurs and healing is progressing (typically occurring in about 5 days). safety and effectiveness have not been established for longer than 5 days for an individual grafting procedure. if allergic manifestations occur during treatment with sulfamylon ® for 5% topical solution, discontinuation of treatment should be considered. if acidosis occurs and becomes difficult to control, particularly in patients with pulmonary dysfunction, discontinuing the soaks with the mafenide acetate solution for 24 to 48 hours may aid in restoring acid-base balance (see precautions section). dressing changes and monitoring the site for bacterial growth during this interruption should be adjusted accordingly.

Contraindications:

Contraindications sulfamylon ® for 5% topical solution is contraindicated in patients who are hypersensitive to mafenide acetate. it is not known whether there is cross sensitivity to other sulfonamides.

Adverse Reactions:

Adverse reactions in the clinical setting of severe burns, it is often difficult to distinguish between an adverse reaction to mafenide acetate and burn sequelae. in a clinical study of pediatric patients with acute burns requiring autografts who received sulfamylon ® for 5% topical solution in addition to double antibiotic solution (dab) wound therapy (neomycin sulfate 40 mg and polymyxin b 200,000 units/liter), the incidence of rash (4.6%) and itching (2.8%) in the group which received sulfamylon ® for 5% topical solution was not different from that experienced with (dab) dressings alone (5.7% and 1.3%, respectively). from other clinical settings, a single case of bone marrow depression and a single case of an acute attack of porphyria have been reported following therapy with mafenide acetate. fatal hemolytic anemia with disseminated intravascular coagulation, presumably related to a glucose-6-phosphate dehydrogenase deficiency, has been reported following therapy with mafenid
e acetate. the following adverse reactions have been reported with topical mafenide acetate therapy: dermatologic and allergic: pain or burning sensation, rash and pruritus (often localized to the area covered by the wound dressing), erythema, skin maceration from prolonged wet dressings, facial edema, swelling, hives, blisters, eosinophilia. respiratory or metabolic: tachypnea, hyperventilation, decrease in pco 2 , metabolic acidosis, increase in serum chloride.

Use in Pregnancy:

Pregnancy teratogenic effects a teratology study performed in rats using oral doses of up to 600 mg/kg/day revealed no evidence of harm to the fetus due to mafenide acetate. there are no adequate data regarding the potential reproductive toxicity of mafenide acetate in a non-rodent species, nor are there adequate and well controlled studies in pregnant women. mafenide acetate should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.

Pediatric Use:

Pediatric use the safety and effectiveness of sulfamylon ® for 5% topical solution have been established in the age groups 3 months to 16 years.

Geriatric Use:

Geriatric use no studies have been conducted to specifically examine the effects of mafenide acetate on burn wounds in geriatric patients.

Overdosage:

Overdosage single oral doses of 2000 mg/kg of mafenide acetate as a 5% solution did not cause mortality or clinical symptoms of toxicity in rats.

Description:

Description mafenide acetate, usp is a synthetic antimicrobial agent designated chemically as α-amino- p -toluenesulfonamide monoacetate. it has the following structural formula: c 7 h 10 n 2 o 2 s●c 2 h 4 o 2 m.w. 246.29 mafenide acetate, usp is a white, crystalline powder which is freely soluble in water. sulfamylon® for 5% topical solution is provided in packets containing 50 g of sterile mafenide acetate to be reconstituted in 1000 ml of sterile water for irrigation, usp or 0.9% sodium chloride irrigation, usp. after mixing, the solution contains 5% w/v of mafenide acetate. the solution is an antimicrobial preparation suitable for topical administration. the solution is not for injection. the reconstituted solution may be held up to 28 days after preparation if stored in unopened containers. once a container is opened, any unused portion should be discarded after 48 hours. store the reconstituted solution at 20° to 25°c (68° to 77°f). limited storage periods at 15° to 30°c (59° to 86°f) are acceptable. structural formula

Clinical Pharmacology:

Clinical pharmacology mechanism of action the mechanism of action of mafenide is not known, but is different from that of the sulfonamides. mafenide is not antagonized by paba, serum, pus or tissue exudates, and there is no correlation between bacterial sensitivities to mafenide and to the sulfonamides. its activity is not altered by changes in the acidity of the environment. the osmolality of the 5% topical solution is approximately 340 mosm/kg. absorption and metabolism applied topically, mafenide acetate diffuses through devascularized areas. approximately 80% of a mafenide acetate dose is delivered to burned tissue over four hours following topical application of the 5% solution. following application of mafenide acetate cream and solution, peak mafenide concentrations in human burned skin tissue occur at two and four hours, respectively. peak tissue concentrations are similar following administration of the solution or cream. once absorbed, mafenide is rapidly converted to an inac
tive metabolite (p-carboxybenzenesulfonamide) which is cleared through the kidneys. clinical studies have shown that when applied topically to burns as an 11.2% mafenide acetate cream, blood levels of the parent drug peaked at 2 hours following application, ranging from 26 to 197 µg/ml for single doses of 14 to 77 g of mafenide acetate. metabolite levels peaked at 3 hours, ranging from 10 to 340 µg/ml. twenty-four hours after application, combined parent and metabolite blood levels had fallen to pretreatment levels. antimicrobial activity mafenide acetate exerts broad bacteriostatic action against many gram-negative and gram-positive organisms, including pseudomonas aeruginosa and certain strains of anaerobes. in vitro cytotoxicity data from in vitro studies on cell culture suggests that mafenide acetate may have a deleterious effect on human keratinocytes. the clinical significance of this information is unknown.

Mechanism of Action:

Mechanism of action the mechanism of action of mafenide is not known, but is different from that of the sulfonamides. mafenide is not antagonized by paba, serum, pus or tissue exudates, and there is no correlation between bacterial sensitivities to mafenide and to the sulfonamides. its activity is not altered by changes in the acidity of the environment. the osmolality of the 5% topical solution is approximately 340 mosm/kg.

Carcinogenesis and Mutagenesis and Impairment of Fertility:

Carcinogenesis, mutagenesis, impairment of fertility no long-term animal studies have been performed to evaluate the carcinogenic potential of mafenide acetate; however, the drug did not induce mutations in l5178ymouse lymphoma cells at the tk locus. animal studies have not been performed to evaluate the potential effects of mafenide acetate on fertility.

How Supplied:

How supplied sulfamylon® (mafenide acetate, usp) for 5% topical solution is available in packets (ndc 51079-624-84) containing 50 g of sterile mafenide acetate to be prepared using 1000 ml sterile water for irrigation, usp or 0.9% sodium chloride irrigation, usp. (see dosage and administration: sulfamylon ® for 5% topical solution: directions for preparation of the solution.) the packets are supplied as follows: carton of five 50 g packets ndc 51079-624-85 recommended storage: packets - store packets in a dry place at room temperature 15° to 30°c (59° to 86°f). prepared solution - store solution at 20° to 25°c (68° to 77°f) with excursions permitted to 15° to 30°c (59° to 86°f). [see usp controlled room temperature.] the solution may be held for up to 28 days if stored in unopened containers. once a container is opened, any unused solution must be discarded within 48 hours. keep this and all medications out of the reach of children. mylan insti
tutional inc. rockford, il 61103 u.s.a. 095.7 revised: 6/2018

Package Label Principal Display Panel:

Principal display panel - 5% topical solution ndc 51079-624-85 sterile sulfamylon ® (mafenide acetate, usp) for 5% topical solution not for injection solution for topical use only net wt. 50 grams sterile powder per packet store packet in a dry place at room temperature 15° to 30°c (59° to 86°f). directions for preparation and storage of the solution - do not use if packet is opened. observe aseptic technique when preparing solution. this packet contains 50 grams of sterile mafenide acetate, usp. open packet and empty entire contents into a suitable container containing 1000 ml of either sterile water for irrigation, usp or 0.9% sodium chloride, usp. mix until completely dissolved. this yields a 5% solution of mafenide acetate, usp. the solution may be held for up to 28 days if stored in unopened containers. once a container is opened, any unused solution must be discarded within 48 hours. store solution at 20° to 25°c (68° to 77°f) excursions 15° to 30°c (59° to 86°f). usual dosage: for dosage and usage information see accompanying prescribing information. keep this and all medications out of the reach of children. rx only 5 packets mylan institutional inc. rockford, il 61103 u.s.a. 565.5 sulfamylon for 5% topical solution


Comments/ Reviews:

* Data of this site is collected from www.fda.gov. This page is for informational purposes only. Always consult your physician with any questions you may have regarding a medical condition.